New radioactive drug targets Hard-to-Treat cancers in early trial

NCT ID NCT06639191

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and side effects, not to cure the disease. Participants receive up to four infusions over several weeks, with close monitoring for any harmful effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical carcinoma cervical squamous cell carcinoma differentiated thyroid carcinoma head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma non-small cell lung carcinoma poorly differentiated thyroid gland carcinoma thyroid gland undifferentiated (anaplastic) carcinoma Uterine Cervical Neoplasms vulva cancer vulvar carcinoma vulvar squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Karolinska University hospital

    RECRUITING

    Stockholm, Stockholm County, 17176, Sweden

    Contact Email: •••••@•••••